Looking for Body Chemistry Patterns in Atrial Fibrillation
Describes metabolic changes over time in adults with atrial fibrillation needing ablation.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- Pessac, FranceSee the site
- Trial code
- Registry title
- Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 10 Mar 2025
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- FA ablation
- Lab test
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have atrial fibrillation and are due to have cardiac ablation. It also seems to include control groups. It studies blood and body-chemistry markers of atrial fibrillation over time.
- Age
- 18 years or older
- Sex
- All genders can join.
Main reasons for not taking part
- Pregnant women
- Endocarditis or pericarditis now or in the last 3 months
- Active tumour disease, benign or malignant
- Chronic inflammation or autoimmune disease
- Chronic liver disease
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years, all genders, and ethnic origins
- Free, informed, and written consent signed
- Person affiliated to or benefiting from a social security scheme
Who cannot take part
- Active tumor pathology (benign or malignant)
- Chronic inflammation or autoimmune disease
- Chronic liver disease
- Myocardial infarction within the last 8 weeks
- Age < 18 years
- Lack of informed consent
- Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)
- Persons under administrative or judicial protection
- Endocarditis or pericarditis in progress or within the 3 last months
Where in France
- University Hospital of BordeauxPessac, FranceContact: Nicolas DERVALTaking people
About the trial
What the trial wants to find out
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
The 2 groups in the trial
- Patients with FAOther group
Patient with a documented Fibrillation Atrial within the last 18 months
Treatment: FA ablation and Lab test
- Patients without FAOther group
Patient without Fibrillation Atrial
Treatment: Lab test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
- Plain-language title
- Looking for Body Chemistry Patterns in Atrial FibrillationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 June 2026